Skye Bioscience Q2 2026 operating loss narrows 39.37% to $11.06 million

• Skye Bioscience posted a Q2 operating loss of USD 11.06 million, narrowing from USD 18.24 million a year earlier.
• Net loss improved to USD 10.79 million from USD 17.62 million in the prior-year quarter.
• Research and development expense plunged 73% to USD 3.94 million due to terminating CBeyond clinical activities and pausing nimacimab R&D.
• General and administrative costs edged down 1% to USD 3.87 million on lower headcount, partly offset by higher legal fees.
• Skye terminated the CBeyond program, paused nimacimab work, and signed a deal to acquire Redx and rebrand as Fibrx Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-056968), on August 14, 2026, and is solely responsible for the information contained therein.